ArticleAnnals of clinical and translational neurology2026
PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycomb group factor 1 (PCGF1) and coiled-coil domain-containing protein 34 (CCDC34) have been implicated in tumorigenesis in multiple malignancies. However, their biological functions and prognostic significance in glioma remain poorly defined.
methodsRNA-sequencing data from glioma cell lines with PCGF1 knockdown were obtained from the GEO database. Correlations between PCGF1 and CCDC34 expression were analyzed using datasets from TCGA, CGGA, and GEO. In addition, RT-qPCR was performed to quantify PCGF1 and CCDC34 expression in glioma specimens. Kaplan-Meier survival analyses were conducted to evaluate the prognostic value of CCDC34. Functional assays were performed using cell lines with PCGF1 or CCDC34 knockdown and overexpression to assess their roles in glioma progression and to elucidate their regulatory relationship. Cell proliferation and colony formation assays were carried out to evaluate tumorigenic capacity.
resultsCCDC34 expression was significantly downregulated in glioma cell lines following PCGF1 knockdown compared with controls. CCDC34 expression positively correlated with WHO tumor grade in glioma. Elevated CCDC34 expression was significantly associated with poorer patient outcomes. Functionally, CCDC34 expression was closely linked to enhanced cell proliferation and colony-forming ability. Rescue experiments demonstrated that PCGF1 promotes glioma cell proliferation in a CCDC34-dependent manner. Gene set enrichment analysis (GSEA) further revealed that both PCGF1 and CCDC34 expression were positively associated with hypoxia, coagulation, and epithelial-mesenchymal transition (EMT) signaling pathways.
conclusionOur findings demonstrate that PCGF1 promotes glioma proliferation in a CCDC34-dependent manner and suggest that CCDC34 may serve as a novel prognostic biomarker and potential therapeutic target in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.